Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
University of California, Davis, Davis, California University of Michigan, Ann Arbor, Michigan University of Minnesota, Minneapolis, Minnesota Washington Center for Bleeding Disorders, Seattle, Washington